Sarcomas represent a rare and heterogeneous disease, and the prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcomas remains poor, with a disease-free survival of less than 10% at 5 years. Only few chemotherapeutic agents have been identified to be active, with reported response rates for doxorubicin, epirubicin and ifosfamide above 20%. Although combination therapy with different chemotherapeutic substances results in higher response rates, superiority against single-agent chemotherapy in terms of survival has not been demonstrated yet. Regarding anthracyclines, and ifosfamide in particular, a dose-response relationship has been shown, and high-dose chemotherapy with stem cell support has also been evaluated by several investigators. However, all studies comprised small patient cohorts and included very heterogeneous histological subtypes of soft-tissue sarcoma. Moreover, randomized trials are missing. Nevertheless, higher doses of chemotherapy result in higher response rates possibly correlating with longer survival. Finally, well-designed randomized trials should be performed, preferably in younger patients and in the context of an interdisciplinary treatment approach. In this review, we provide an overview of the literature concerning high-dose chemotherapy with hematopoietic stem cell support in the treatment of bone and soft-tissue sarcomas. On the basis of our own data, we would like to emphasize the importance of high-dose chemotherapy in the treatment of sarcomas.

Keywords:
Bone sarcomas, High-dose chemotherapy, Review, Soft-tissue sarcomas, Stem cell support
1.
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens – A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999;17:150–157.
2.
Edmonson JH, Ryan LM, Blum RG, Brooks JS, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11: 1269–1275.
3.
Antman KH, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276–1285.
4.
Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al: Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537–1545.
5.
Bui NB, Demaille MC, Chevreau C, Blay JY, Cupissol D, Rios M, Thyss A, Maugard C, Bastit P, Bay JO, Tanguy A, Fargeot P, Lortholary A, Bonichon F: qMAID vs MAID + 25% in adults with advanced soft tissue sarcoma (STS): First results of a randomized study of the FNCLCC Sarcoma Group (abstract 1991). Proc Am Soc Clin Oncol 1998;17:517a.
6.
Blay JY, van Glabbeke M, Nielsen OS, van Oosterom AT, Tursz T, Oosterhuis JW, Verweij J: Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: A study on 1742 patients (STBSG) (abstract 1973). Proc Am Soc Clin Oncol 1998;17:512a.
7.
Standard-Options-Recommandations, vol 1: Sarcome des Tissus Mous et Ostéosarcomes. Paris, Arnette/Blackwell, 1995, pp 1–113.
8.
Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995;9:765–785.
9.
Verweij J, Mouridsen HT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT, van Glabbeke M, Tursz T: The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995;20:193–201.
10.
Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS: Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506–2511.
11.
Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies – Dose-response and schedule dependence. J Clin Oncol 1997;15:2378–2384.
12.
Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600–1608.
13.
Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R, Soderberg M, Wist E, Raabe N, Erlanson M, Solheim OP, Hannisdal E: Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997;33:1551–1558.
14.
Jelic S, Kovcin V, Milanovic N, Babovic N, Kreacic M, Ristovic Z, Vlajic M, Filipovic-Ljeskovic I: Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220–225.
15.
Reichardt P, Tilgner J, Hohenberger P, Dorken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998;16:1438–1443.
16.
Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steiss RG, et al: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing’s sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911–1918.
17.
Burdach S, Jurgens H, Peters C, Nürnberger W, Mauz-Korholz C, Korholz D, Paulussen M, Pape H, Dilloo D, Koscielniak E, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 1993;11:1482–1488.
18.
Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, Abramson SJ, Gerald WL, Small TN, Gillio AP, Gulati SC, O’Reilly RJ, Ghavimi F: High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998;16:1697–1706.
19.
Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, Palmero A, Biasin E, Bacci G, Picci P, Madon E: High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study. J Clin Oncol 2001;20:2150–2156.
20.
Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001;27:933–937.
21.
Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221–1227.
22.
Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E 3rd, et al: Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15:373–379.
23.
Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T: High dose chemotherapy with ABMT in soft tissue sarcomas: A report of 22 cases. Bone Marrow Transplant 1992;10:405–408.
24.
Mesia R, Sola C, Lopez Pousa A, Mendoza L, Bellet M, Andres L, Lopez Lopez JJ: High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas (in Spanish). Rev Clin Esp 1994;194:960–965.
25.
Wiklund T, Saeter G, Strander H, Alvegard T, Blomqvist C: The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery: The Scandinavian Sarcoma Group experience. Eur J Cancer 1997;33:357–361.
26.
Seynaeve C, Verweij J: High-dose chemotherapy in adult sarcomas: No standard yet. Semin Oncol 1999;26:119–133.
27.
Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000;18:3643–3650.
28.
Elias AD, Ayasj LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al: A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991;9:320–327.
29.
Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E, Crown J, Dazzi C, Cariello A, Marangolo M: High-dose chemotherapy for solid tumors: Results of the EBMT. Crit Rev Oncol Hematol 2002;41:129–140.
30.
Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002;41:157–167.
31.
Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004;34:37–41.
32.
Vogt T, Hafner C, Bross K, Bataille F, Jauch K-W, Landthaler M, Andreesen R, Reichle A: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003;98:2251–2256.
33.
Reichle A, Vogt T, Bross K, Bataille F, Berand A, Zaiss M, Wagner H, Krause SW, Andreesen R: Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in second line therapy of advanced melanomas and pre-treated soft-tissue sarcomas. Onkologie 2003;26:V382.
34.
Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, Inoue H: Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. Br J Cancer 2002;86:1303–1309.
35.
Masferrer J: Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001;7:S144–S150.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.